RELATIONSHIP BETWEEN PARATHYROID HORMONE, VITAMIN-D, CALCIUM AND PHOSPHORUS IN CKD Neeraja Kunireddy, Priscilla Abraham Chandran, Sree Bhushan Raju, M.Noorjahan.

Slides:



Advertisements
Similar presentations
1 Secondary hyperparathyroidism (SHPT): Assessing the educational support requirements for nurses across Europe A joint EDTNA/ERCA & Amgen (Europe) GmbH.
Advertisements

Bone Disease in Renal Failure Dr Anne Kleinitz and Dr Cherelle Fitzclarence
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD)
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Assessment of renal function Jack Shepard Jayne Windebank.
Kidney Function Tests Rana Hasanato, MD, KSFCB
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Effect of cinacalcet on bone markers in a maintenance haemodialysis patient Solenn Pelletier, MD and Denis Fouque, MD, PhD Hôpital E. Herriot Lyon, France.
Chronic Kidney Disease-Mineral and Bone Disorder
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
AfterBefore PTH pg/ml PTH pg/ml AfterBefore Case Report 1) Age 53, 17 yrs HIV infection TDF/FTC/EFZ Baseline 25(OH)D.
CASE 1. Donald is a 68 year-old man who is admitted to hospital via the Emergency Department one day, following a myocardial infarction. Subsequent investigation.
... Assessing renal function in the elderly The development of a new Iohexol based method to measure the true Glomerular Filtration Rate Gijs Van Pottelbergh,
Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.
Parathormone (PTH) and electrolytes in end stage renal disease (ESRD) and hemodialysis (HD) patients. Focus on magnesium Coordinator: Gliga Mirela MD,Phd.
Section 5: Configuration of healthcare to manage CKD.
ASSOCIATION OF HYPOVITAMINAEMIA D AND TRANSFORMING GROWTH FACTOR – β1 IN THE PROGRESSION OF CHRONIC KIDNEY DISEASE Grigorios G. Dimas 1, Ilias E. Kanellos.
This article and any supplementary material should be cited as follows: Oleson CV, Seidel BJ, Zhan T. Association of vitamin D deficiency, secondary hyperparathyroidism,
Co-authors: Drs. K.A. Parvathy, C.V.Harinarayan, B. Vengamma, Bindu Menon, U.V. Prasad,G. Hima Bindu NUTRITIONAL STATUS IN ADOLESCENTS WITH EPILEPSY Presented.
CKD Dr;BASHARDOOST. CKD –SOME DEFINITIONS IRREVERSIBLE LOSS OF GFR CKD results when a disease process damages the structural or functional integrity of.
FIBROBLAST GROWTH FACTOR-23 AND HYPOVITAMINAEMIA D IN ANAEMIA OF TYPE 2 DIABETIC NEPHROPATHY Grigorios G. Dimas 1, Fotios S. Iliadis 1, Ilias E. Kanellos.
A R ETROSPECTIVE R EVIEW OF THE IMPLEMENTATION OF A VITAMIN D SUPPLEMENTATION POLICY IN CHILDREN WITH CHRONIC RENAL IMPAIRMENT. Sandra H. Geraghty, Clinical.
Comparison of Asymmetric DimethylArginine Levels and Coronary Artery Calcifications in Different Stages of Chronic Kidney Disease and Kidney Transplantation.
1 Antonio Bellasi, MD Medical manager Genzyme, Italy Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD)
Secondary Hyperparathyroidism in CKD: Usefulness of VDR Agonists Reference: Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin d.
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
Vitamin D deficiency and anemia in early chronic kidney disease 2010/05/18 R4 이완수 2010.
The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.
Daniel Bikle, John Adams, and Sylvia Christakos
CKD Treatment 순천향 대학교병원 신장내과 R3 김재연. Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic processes associated with abnormal.
Volume 79, Pages S3-S8 (April 2011)
Chronic Kidney disease
³Emergency Medicine Department of Istria, Umag, Croatia
The ECHO Observational Study
CARDIOVASCULAR CORELATIONS IN CHILDREN WITH END STAGE RENAL DISEASE
Introduction CKD-MBD. Introduction CKD-MBD Regulation of PTH Secretion.
Volume 67, Pages S1-S7 (June 2005)
Chronic kidney disease and pre-dialysis
Acute and Chronic Renal Failure
Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation  Jordi Bover,
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Bone metabolism and disease in chronic kidney disease
Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician  Joseph A. Vassalotti, MD, Robert Centor, MD,
Fibroblast Growth Factor 23 and CKD Prognosis
Guidelines American Journal of Kidney Diseases
Phosphorus: Another Devil in Our Diet?
FGF23 or PTH: which comes first in CKD ?
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Figure 4 Model of changes in the serum levels
Volume 79, Pages S3-S8 (April 2011)
Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012.
Chapter 3: Management of progression and complications of CKD
Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients  Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa.
Volume 71, Issue 1, Pages (January 2007)
Volume 79, Pages S20-S23 (April 2011)
Use of vitamin D in chronic kidney disease patients
American Journal of Kidney Diseases
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD 
Volume 56, Issue 3, Pages (September 1999)
Mineral metabolism in CKD: adaptation devolves into maladaptation.
CKD Is a Global Burden With Major Implications
Attributable risk for disorders of mineral metabolism.
Presentation transcript:

RELATIONSHIP BETWEEN PARATHYROID HORMONE, VITAMIN-D, CALCIUM AND PHOSPHORUS IN CKD Neeraja Kunireddy, Priscilla Abraham Chandran, Sree Bhushan Raju, M.Noorjahan. DEPARTMENT OF BIOCHEMISTRY NIZAM’S INSTITUTE OF MEDICAL SCIENCES, HYDERABAD. Introduction  Chronic kidney disease -mineral bone disorders (CKD-MBD) is defined as a systemic disorder of mineral and bone metabolism associated with abnormalities of calcium, phosphorus, PTH or vitamin D metabolism.  Secondary hyperparathyroidism(SHPT) is an overproduction of PTH caused by several changes that occur in bone and mineral metabolism as a result of decreased kidney function.  In addition to bone mineral defects and disease, alterations in calcium, phosphorus, vitamin D, and PTH cause other deleterious consequences primarily cardiovascular calcification and is directly correlated to increase in morbidity and mortality.  Identifying patients at risk and evaluating for SHPT is important because early intervention slows or arrests the progression of bone and cardiac disease in CKD patients. Aims & Objectives  The aim is to evaluate the relationship between bone markers (iPTH, vitamin-D, calcium and phosphorus) in various stages of CKD. Materials & Methods  A total of 123 CKD patients which are divided into stage III (n=19), stage IV ( n=27), stage V( n=77) are included in the study.  They are classified in to three groups based on eGFR.  eGFR calculated by MDRD 6-variable equation. GFR (mL/min/1.73 m 2 ) = 170X(S.Cr / 88.4) X age X (SU X 2.78) X albumin X (0.762,if F) (1.18, if African American).  Serum urea, creatinine, albumin, iPTH, 25(OH) D 3, calcium and phosphorus were estimated.  Serum creatinine was estimated by Jaffe’s kinetic method (traceble to IDMS) on Siemens Dade Dimension analyzer.  Serum urea was estimated by enzymatic kinetic UV assay.  Calcium, phosphorus was estimated by Colorimetric assay with endpoint determination.  iPTH, VITAMIN-D were determined by ELECTROCHEMILUMNICENT IMMUNOASSAY.  Pearson’s correlation and ANOVA test are used to assess the relation between the parameters. Results Mean±SD values of various parameters in different stages of CKD are:  Statistical significant difference is found with iPTH and phosphorus among different stages of CKD. Statistically significant negative correlation was found between iPTH and eGFR, phosphorus and eGFR. Discussion  CKD-MBD refers to the changes in bone, and it is a multifactorial disorder resulting from abnormalities in mineral metabolism, includes vitamin and calcitriol deficiency, hyperparathyroidism, disordered phosphate and calcium metabolism,and elevated fibroblastic growth factor 23 (FGF23)(1).  PTH is the most important regulator of calcium metabolism. Hyperparathyroidism that develops relatively early in CKD is the major driving force in the development of osteitis fibrosa(1).  In our study, Serum phosphorus showed a statistically significant correlation with eGFR.  When GFR falls, the phosphorus clearance decreases significantly, leading to phosphorus retention(2). Conclusions Our study shows importance of the determination of iPTH and phosphorus for early detection of SHPT. iPTH level are increased earlier than other bone markers. Early screening of CKD patients with serum iPTH levels helps in early detection and intervention of SHPT which reduces considerable mortality and morbidity. References 1.Study of possible correlation between inflammation and bone mineral disorders in Chronic Kidney Disease.Said S.Khamis1,Hany S. Elbarbary1,Mahmoud M. Emara1, Enas S. Essa2 and Ahmed A.Zayed1 International Journal of Recent Scientific Research, July, Relationship Between Serum Parathyroid Hormone Levels, Vitamin D Sufficiency, and Calcium Intake. Laufey Steingrimsdottir, PhD Orvar Gunnarsson, MD Olafur S. Indridason, MD, MHS Leifur Franzson, MSc, Pharm Gunnar Sigurdsson, MD, PhD. JAMA REG No:14370